Posted by Michael Wonder on 25 Oct 2023
Akebia receives FDA acceptance of resubmission to NDA of vadadustat for the treatment of anaemia due to chronic kidney disease
25 October 2023 - 27 March 2024 set as user fee goal date.
Akebia Therapeutics today announced the US FDA has acknowledged that the resubmission to its new drug application for vadadustat as a treatment for anaemia due to chronic kidney disease in adult patients on dialysis, was complete.
